Cyxone’s Annual General Meeting moved to June 5, 2018
Cyxone announced today that the date of the company's Annual General Meeting (AGM) will be changed to June 5, 2018 due to the intensification of the work related to the financing of the company's drug candidate Rabeximod.
The shareholders of Cyxone AB (publ) are hereby informed that the company's Annual General Meeting (AGM) will be postponed and held on Tuesday, June 5, 2018. It was previously scheduled for May 23, 2018. The reason for the time shift is derived from the in-depth work related to the financing of the company's drug candidate Rabeximod, which was acquired in 2017. Cyxone intends to raise funding to initiate a Phase 2b clinical trial for the drug candidate Rabeximod as a treatment for the autoimmune disease rheumatoid arthritis.
A formal notice convening the Annual General Meeting on June 5, 2018 will be published approximately four weeks before that day.
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
221 22 Malmö
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase 2 program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000.